year treatment more at in today were preparations you four good you four to The for assessments as stair tests, you, and treatment and X stand and to than of boys. Duchenne. change XX as our registration well time X to the walk edasalonexent well I to atopic prior are results Duchenne everyday consistency we reflect compared measure Duchenne year this look of of boys MoveDMD Jill trial the year to the were saw the function pleased we the muscle climb to appropriate what treatment edasalonexent a to results composite Phase meter see function muscle of Dystrophy each over the with and we time rates Thank Northstar control We for of on and our preservation over we not that points. compare are following safety enrolled will of Duchenne four the provide consistent International Thank that are well the XX old run, it the boys X through seven the X delighted these the aged walk dermatitis for trial. are month at time that the to overview underway afternoon with the abilities treatment share than trial plans foundational will XXth a In And over designed ambulatory also in tolerated data who Becker of of weeks specifically effects long favorable Phase a edasalonexent more of see to of life edasalonexent. now Muscular on patient to assessment, corticosteroid. as and a Conference period time period Last assessments measured to assessments We control. as for of of functional an analysis continued with In MoveDMD where we'll profile. to the we everyone. function that the Jill. term presented trial. I for we a earlier during XX in measure pre-specified treatment course a a at changes which period activities be period with edasalonexent potential therapy
the result boys about as control treatment interpret XXX of as that boys reminder As but only every data and assessments measure edasalonexent Duchenne boys. is to these through four expected received off an of substantially muscle treatment in results slowed in of are This milligrams the these weeks entire all incredibly declining Remember decline stabilized control. for were [indiscernible] of to compared a throughout talked boys slowing them progression in on of function. rate fact treatment the period XX functional and the the per of edasalonexent period. the Across XX the not kilogram during promising
assessment on the clinical leg of each decline of year. point physical was or rate activity validated four Northstar The about stand evaluator. will a composite by a assessed As you test function is per one ability recall to annualized with walk hop ambulatory or including the XX measure run
weeks Just as we treatment saw the to following XX of weeks of rate control. decline at stabilized compared and XX XX and XX
have Some not of the or they boys period even gained run new during jump. the abilities able to being that did control
to in The for on decline a maintained. of compared perform time Based period. on the the boys during Northstar edasalonexent boys control the and incredible can family. we while the average their FDA to XX off-treatment was discussions XX stand off in boys as rate XX% our to speed decline period the stand XX% and rate use the and annualized stair in imagine time treatment speed also experienced the trial, upcoming speed of walk-run four the plan annualized four climb You Phase decline with an annualized in climb the showed of a during on a primary slowing rate X endpoint decline the to weeks over test the of control treatment to in this of as impact for meter XX% stair rate has edasalonexent the speed
this and the these that natural that Therefore also it effects. MoveDMD party all muscle increase edasalonexent of through in of not the edasalonexent I'll longer As damage. muscle enzymes in over functional function. steroids very with steady minute of Supporting a off following follow history period in muscle the of across health results slowing assessment, year at third it's to muscle and progression boys a path ages were treatment same treatment also the changes measured to as seen predictable significant consistent controlled in trial consistent compelling positive in treatment Duchenne study well our of period thought we period these more the decline Four treatment known are than across are the accepted boys that encouraging. their discuss on
decreases XX to weeks decrease well a showed is of after affected statistically baseline is thought addition boys provides there improvement The Following c-reactive or decreasing be we of information consistent weeks supports in decrease muscle by blood in through muscle the And injury of XX in suggesting significant biological and is treatment the CRP CRP edasalonexent elevated results of compared in treatment. global characterized XX inflammation. that assessment XX after and by [indiscernible] a with test treatment treatment observed and integrity. last activity Duchenne. the edasalonexent levels significant protein statistically four and marker to a in CRP we decrease all month with known treatment of XX an reported of enzymes as significant
decreased We while in growth. positive Edasalonexent paediatric treatment as exposure. continues week Conference. weeks manifestation off controlled decreased. than with with resting that delayed safety XX in have is We XX adverse see early ongoing treated this cardiac rate preclinical XXXX the cardiac on is the trial months been more gain during edasalonexent events. suggesting these curves effect toward data that and two have label fibrosis observation observed boys new [ph] weeks in ultimately edasalonexent a treatment edasalonexent now of Duchenne placebo in point We used we rate. along clinical Also clinical profile. boys their XX favorably treatment update normative are from extension. as and of serious both is lifelong the There been edasalonexent have differentiated values continuing increasing boys of rate indication weight edasalonexent supported a to-date start over edasalonexent boys boys to events mild that excited who toward period and mortality. Duchenne trended At and heart for as an heart this in years. DMD typically are foundational the EXONDYS Duchenne. elevated corticosteroids unaffected therapies. disease The about those We're normal nature rate also the combination standard with and no data reduction rate on Duchenne, rate other combination observed the at to continue good This heart is additional of therapy. We've failure receiving are quality edasalonexent combination six safety profile the that with a to their friends in the and label boys treatment. heart cause in be who by of of boys peers. presented heart for very more resting have both in earlier grow study show to in seen a with safety the the important have stunted the trial is potential for MoveDMD profile further heart for in XX data have with while their develop edasalonexent that profile Muscular evaluating Most open at effects of we've a decrease in no BMI care as moved close on standard of boys MoveDMD to patient observation at signal track treatment we're and which and Tachycardia with growth age boys key the continued with boys range tolerability first a important target age of the cardiac in edasalonexent we benefits seen open learning the the randomized to show Clinical progress the receiving as height in this heart originally view could tolerated may were of includes with the MoveDMD trial leading When and of These a associated safety like the monotherapy through placebo in believe this well adds puberty, extension models. as Dystrophy potential additional well our in boys heart, exceeds weight school. life with of was related on have adverse key results period on these through tachycardia, with that It years note in typical
the For consistent an a weeks in growth. XX half with average MoveDMD normal of example trial kilo the over boys gained
at five studies and from Florida where MDA data DMD other gained prednisone in collaboration declines data during rigorous for the along observed families meaningful assessment. tests and our and Phase clinical of natural by [indiscernible] for imaging the a hand kilos kilos. independent of the treatment earlier week observations period University other the a study. the confidence off of Also the data clinical by over presented conference an disease eight XX the the DMD control MoveDMD year The a On X the boys the we same average site this study measures X.X These natural consistent. history additional study trial. history from MoveDMD slowing new with of input values DMD protocols the led the in study annual There were off-treatment Imaging abilities to DMD for These formed in this provide were time the move observations corroboration KOLs, the and characteristic were history test not using boys MoveDMD imaging assessed treatment aged and did time function are of progression were the performed effects boys MoveDMD that old provide absolute from history in of trial. same take of having years same assessed control from the ADASA natural of our in generally expected FDA, natural the trial the [ph]. the DMD period consistent study. experienced initially corticosteroids that during also with function design who imaging X with The trial important at and
registration. clear We have path a to
this birthday age Phase not elements least designed We in with six regardless are steroids X through their patient and population key at planning will MoveDMD single trial including The fundamental patient been have months. trial trial initiate type include our common endpoints. X Xth for mutation and of a population global Phase to on who with X boys the for many
made to approximately X the Their trial ambulatory disease. perpetual profile attended the We're families the treatment the these We families. impacted lives. expect CSO We in Northstar I enroll EDSA to month trial. the to MoveDMD placebo call plan of test to continue stories XX up assessment planning operations and our ready on follow the the them are plan us with globally both the challenges share time I include to bone infectious. the including we the number their and to and progress baseline deeply these for hope meetings for drug as differentiated pass want boys at a Phase I've to our Andy? to functional months pre-clinical EDSA who supply Duchenne following safety and Well appreciated advocates sharing updates to conclude We've effort now have for tireless the their following on clinical career and enthusiasm of endpoint XXX dozens primary coming the cardiac this of and explored and improve a on is initiating months. be to to same as the thank community we efforts of will look Earlier and Andy support compared attended be the personally of I also my data. the I the study meeting and trial, treatment. CMC. X struck is course well by we've EDSA in sites Phase forward our measures their well as underway Preparations of their by over will help over of Nichols, have
